Literature DB >> 1392452

The metabolism of tramadol by human liver microsomes.

W D Paar1, P Frankus, H J Dengler.   

Abstract

The metabolism of tramadol was investigated in vitro using microsomal fractions of human liver. The parent compound and its main metabolites were determined by a newly developed high performance liquid chromatography assay. O-demethylation of tramadol was found to be stereoselective. The Vmax of the O-demethylation of (-)-tramadol was 210 pmol.mg-1.min-1, whereas (+)-tramadol was O-demethylated with a Vmax of 125 pmol.mg-1.min-1. The Km for both enantiomers was determined to be 210 microM. O-demethylation was inhibited competitively by quinidine (ki = 15 nM) and propafenone (ki = 34 nM). N-demethylation was also stereoselective, preferentially metabolizing the (+)-enantiomer. Whereas O-demethylation displayed monophasic Michaelis-Menten kinetics, N-demethylation was best described by a two-site model. Competitive inhibition of the O-demethylation both by quinidine and propafenone suggests that O-demethylation is carried out by P-450IID6.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1392452     DOI: 10.1007/bf00180294

Source DB:  PubMed          Journal:  Clin Investig        ISSN: 0941-0198


  7 in total

Review 1.  The genetic polymorphism of debrisoquine/sparteine metabolism--clinical aspects.

Authors:  M Eichelbaum; A S Gross
Journal:  Pharmacol Ther       Date:  1990       Impact factor: 12.310

2.  In vitro characterization of the human cytochrome P-450 involved in polymorphic oxidation of propafenone.

Authors:  H K Kroemer; G Mikus; T Kronbach; U A Meyer; M Eichelbaum
Journal:  Clin Pharmacol Ther       Date:  1989-01       Impact factor: 6.875

3.  Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes.

Authors:  S V Otton; H K Crewe; M S Lennard; G T Tucker; H F Woods
Journal:  J Pharmacol Exp Ther       Date:  1988-10       Impact factor: 4.030

4.  Characterization of a common genetic defect of cytochrome P-450 function (debrisoquine-sparteine type polymorphism)--increased Michaelis is Constant (Km) and loss of stereoselectivity of bufuralol 1'-hydroxylation in poor metabolizers.

Authors:  P Dayer; R Gasser; J Gut; T Kronbach; G M Robertz; M Eichelbaum; U A Meyer
Journal:  Biochem Biophys Res Commun       Date:  1984-11-30       Impact factor: 3.575

5.  [Biotransformation of tramadol in man and animal (author's transl)].

Authors:  W Lintz; S Erlaçin; E Frankus; H Uragg
Journal:  Arzneimittelforschung       Date:  1981

Review 6.  Genetic polymorphisms of drug metabolism.

Authors:  U A Meyer
Journal:  Fundam Clin Pharmacol       Date:  1990       Impact factor: 2.748

7.  A sensitive capillary GC assay for the determination of sparteine oxidation products in microsomal fractions of human liver.

Authors:  B A Osikowska-Evers; M Eichelbaum
Journal:  Life Sci       Date:  1986-05-12       Impact factor: 5.037

  7 in total
  28 in total

1.  Metabolic assessment in liver microsomes by co-activating cytochrome P450s and UDP-glycosyltransferases.

Authors:  Z Yan; G W Caldwell
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2003 Jul-Sep       Impact factor: 2.441

Review 2.  The role of tramadol in cancer pain treatment--a review.

Authors:  Wojciech Leppert; Jacek Łuczak
Journal:  Support Care Cancer       Date:  2004-11-18       Impact factor: 3.603

3.  Influence of bile acid derivates on tramadol analgesic effect in mice.

Authors:  V Vasovic; Sasa Vukmirovic; M Pjevic; I Mikov; M Mikov; V Jakovljevic
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2010-09       Impact factor: 2.441

Review 4.  Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping.

Authors:  D Frank; U Jaehde; U Fuhr
Journal:  Eur J Clin Pharmacol       Date:  2007-02-02       Impact factor: 2.953

5.  Two separate dose-dependent effects of paroxetine: mydriasis and inhibition of tramadol's O-demethylation via CYP2D6.

Authors:  Anette Green Nielsen; Rasmus Steen Pedersen; Lene Noehr-Jensen; Per Damkier; Kim Brosen
Journal:  Eur J Clin Pharmacol       Date:  2010-03-31       Impact factor: 2.953

6.  Inhibition of CYP2D6-mediated tramadol O-demethylation in methadone but not buprenorphine maintenance patients.

Authors:  Janet K Coller; Jennifer R Michalakas; Heather M James; Aaron L Farquharson; Joel Colvill; Jason M White; Andrew A Somogyi
Journal:  Br J Clin Pharmacol       Date:  2012-11       Impact factor: 4.335

7.  Ticlopidine inhibits both O-demethylation and renal clearance of tramadol, increasing the exposure to it, but itraconazole has no marked effect on the ticlopidine-tramadol interaction.

Authors:  Nora M Hagelberg; Tuukka Saarikoski; Teijo I Saari; Mikko Neuvonen; Pertti J Neuvonen; Miia Turpeinen; Mika Scheinin; Kari Laine; Klaus T Olkkola
Journal:  Eur J Clin Pharmacol       Date:  2012-10-26       Impact factor: 2.953

8.  Tramadol metabolism to O-desmethyl tramadol (M1) and N-desmethyl tramadol (M2) by dog liver microsomes: Species comparison and identification of responsible canine cytochrome P-450s (CYPs).

Authors:  Tania E Perez Jimenez; Katrina L Mealey; Tamara L Grubb; Stephen A Greene; Michael H Court
Journal:  Drug Metab Dispos       Date:  2016-10-06       Impact factor: 3.922

Review 9.  The Pharmacogenetics of Tramadol.

Authors:  Dorte Lassen; Per Damkier; Kim Brøsen
Journal:  Clin Pharmacokinet       Date:  2015-08       Impact factor: 6.447

10.  Uptake/efflux transport of tramadol enantiomers and O-desmethyl-tramadol: focus on P-glycoprotein.

Authors:  Mouna Kanaan; Youssef Daali; Pierre Dayer; Jules Desmeules
Journal:  Basic Clin Pharmacol Toxicol       Date:  2009-05-26       Impact factor: 4.080

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.